Taipei 505(b)(2) Seminar

On Tuesday, December 12, 2017, Camargo CEO and President Ken Phelps gave a seminar on drug development opportunities utilizing 505(b)(2), for 100 attendees.

This seminar benefited executives at Biotech and Pharmaceutical companies interested in learning more about 505(b)(2) drug development, which enables a lower cost, lower risk, and faster path to regulatory approval and market.

Download This Presentation